Page last updated: 2024-11-12
ar-709
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 11226413 |
CHEMBL ID | 242199 |
SCHEMBL ID | 3258035 |
MeSH ID | M0593065 |
Synonyms (13)
Synonym |
---|
5-chloro-3-({4-[(2,4-diaminopyrimidin-5-yl)methyl]-6,7-dimethoxy-1-benzofuran-2-yl}methyl)-n,n-dimethyl-1h-indole-2-carboxamide |
bdbm18071 |
ar-709 |
CHEMBL242199 |
952042-29-4 |
unii-qua6ejn8tl |
663214-64-0 |
1h-indole-2-carboxamide, 5-chloro-3-((4-((2,4-diamino-5-pyrimidinyl)methyl)-6,7-dimethoxy-2-benzofuranyl)methyl)-n,n-dimethyl- |
qua6ejn8tl , |
SCHEMBL3258035 |
Q27287499 |
5-chloro-3-[[4-[(2,4-diaminopyrimidin-5-yl)methyl]-6,7-dimethoxy-1-benzofuran-2-yl]methyl]-n,n-dimethyl-1h-indole-2-carboxamide |
DTXSID401026061 |
Research Excerpts
Bioavailability
After IV administration, clearance of AR-709 was 496 mL/min. Volume of distribution was 1,700 L and the absolute oral bioavailability was 2.
Excerpt | Reference | Relevance |
---|---|---|
"To explore, in a microdose (phase-0) study, the pharmacokinetics, bioavailability and concentrations in key compartments of the lung, of AR-709, a novel diaminopyrimidine antibiotic for the treatment of respiratory infection." | ( A microdose study of ¹⁴C-AR-709 in healthy men: pharmacokinetics, absolute bioavailability and concentrations in key compartments of the lung. Boyce, MJ; Lappin, G; Lociuro, S; Matzow, T; Seymour, M; Warrington, SJ, 2013) | 0.9 |
" Its low oral bioavailability however, precludes oral administration." | ( A microdose study of ¹⁴C-AR-709 in healthy men: pharmacokinetics, absolute bioavailability and concentrations in key compartments of the lung. Boyce, MJ; Lappin, G; Lociuro, S; Matzow, T; Seymour, M; Warrington, SJ, 2013) | 0.69 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (27)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID519207 | Antibacterial activity against penicillin intermediate Streptococcus pneumoniae by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | In vitro activity of AR-709 against Streptococcus pneumoniae. |
AID519208 | Antibacterial activity against penicillin resistant Streptococcus pneumoniae by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | In vitro activity of AR-709 against Streptococcus pneumoniae. |
AID520406 | Antimicrobial activity against quinolone-resistant Streptococcus pneumoniae by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Antistreptococcal activity of AR-709 compared to that of other agents. |
AID520405 | Antimicrobial activity against quinolone-susceptible Streptococcus pneumoniae by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Antistreptococcal activity of AR-709 compared to that of other agents. |
AID519214 | Antibacterial activity against amoxicillin-clavulanic acid susceptible Streptococcus pneumoniae by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | In vitro activity of AR-709 against Streptococcus pneumoniae. |
AID520414 | Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Antistreptococcal activity of AR-709 compared to that of other agents. |
AID519210 | Antibacterial activity against cotrimoxazole intermediate Streptococcus pneumoniae by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | In vitro activity of AR-709 against Streptococcus pneumoniae. |
AID519212 | Antibacterial activity against azithromycin susceptible Streptococcus pneumoniae by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | In vitro activity of AR-709 against Streptococcus pneumoniae. |
AID519217 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | In vitro activity of AR-709 against Streptococcus pneumoniae. |
AID520407 | Antimicrobial activity against trimethoprim-sulfamethoxazole-susceptible Streptococcus pneumoniae by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Antistreptococcal activity of AR-709 compared to that of other agents. |
AID297557 | Inhibition of Bacillus anthracis DHFR | 2007 | Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18 | Crystal structure of the anthrax drug target, Bacillus anthracis dihydrofolate reductase. |
AID519213 | Antibacterial activity against azithromycin resistant Streptococcus pneumoniae by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | In vitro activity of AR-709 against Streptococcus pneumoniae. |
AID520409 | Antimicrobial activity against macrolide-susceptible Streptococcus sp. 'group A' by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Antistreptococcal activity of AR-709 compared to that of other agents. |
AID519206 | Antibacterial activity against penicillin susceptible Streptococcus pneumoniae by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | In vitro activity of AR-709 against Streptococcus pneumoniae. |
AID519205 | Antibacterial activity against Streptococcus pneumoniae by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | In vitro activity of AR-709 against Streptococcus pneumoniae. |
AID519216 | Antibacterial activity against multidrug resistant Streptococcus pneumoniae by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | In vitro activity of AR-709 against Streptococcus pneumoniae. |
AID520413 | Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Antistreptococcal activity of AR-709 compared to that of other agents. |
AID520412 | Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Antistreptococcal activity of AR-709 compared to that of other agents. |
AID520403 | Antimicrobial activity against macrolide-susceptible Streptococcus pneumoniae by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Antistreptococcal activity of AR-709 compared to that of other agents. |
AID519211 | Antibacterial activity against cotrimoxazole resistant Streptococcus pneumoniae by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | In vitro activity of AR-709 against Streptococcus pneumoniae. |
AID520408 | Antimicrobial activity against trimethoprim-sulfamethoxazole-resistant Streptococcus pneumoniae by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Antistreptococcal activity of AR-709 compared to that of other agents. |
AID520404 | Antimicrobial activity against macrolide-resistant Streptococcus pneumoniae by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Antistreptococcal activity of AR-709 compared to that of other agents. |
AID519066 | Antibacterial activity against multidrug resistant Streptococcus pneumoniae ATCC 49619 by CLSI microdilution susceptibility testing method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Activity of the Diaminopyrimidine AR-709 against recently collected multidrug-resistant isolates of invasive Streptococcus pneumoniae from North America. |
AID520410 | Antimicrobial activity against macrolide-resistant Streptococcus sp. 'group A' by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Antistreptococcal activity of AR-709 compared to that of other agents. |
AID519215 | Antibacterial activity against amoxicillin-clavulanic acid resistant Streptococcus pneumoniae by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | In vitro activity of AR-709 against Streptococcus pneumoniae. |
AID519209 | Antibacterial activity against cotrimoxazole susceptible Streptococcus pneumoniae by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | In vitro activity of AR-709 against Streptococcus pneumoniae. |
AID520411 | Antimicrobial activity against Streptococcus pneumoniae assessed as time required to show antibiotic effect | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Antistreptococcal activity of AR-709 compared to that of other agents. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (66.67) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 17.48
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.48) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (16.67%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (83.33%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |